Navigation Links
Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients

- Data presented at 12th Congress of European Hematology -

CHESHIRE, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced results from three analyses of Phase III studies examining Soliris(TM) (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) at the 12th Congress of European Hematology, organized by The European Hematology Association (EHA) in Vienna. These presentations included:

"The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)," presented by Dr. Peter Hillmen of the General Infirmary at the University of Leeds, Leeds, UK.(1) (Abstract No. 0380)

"Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study Results," presented by Dr. Hubert Schrezenmeier of the University Hospital Ulm in Ulm, Germany.(2) (Abstract No. 0378)

"The Clinical Benefit of Eculizumab Is Demonstrable in all Subpopulations of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) with Hemolysis," presented by Dr. Petra Muus of Radboud University, Nijmegen, Netherlands.(3) (Abstract No. 0379) Subpopulations were diverse and included patients with poor bone marrow function, smaller PNH clone sizes, low levels of hemolysis, less anemia, minimal pre-treatment transfusion requirements and those receiving steroids or erythropoietin.

Dr. Muus noted, "In published clinical trials, Soliris significantly reduced hemolysis in all PNH patients, which led to an improvement in anemia, patient functioning and quality of life, and fewer thrombotic events. Research presented this week at the Congress in Vienna described the impact of Soliris on multiple subgroups of PNH patients and showed that the effect of Soliris was maintained across all subpopulations including in those patients who had as
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:10/10/2008)..., Oct. 10 /- Boston Scienti...schedule of the Company,s major,events and press a...tion,s,(CRF) twentieth annual Transcatheter Cardio...which runs from October 12 to 17 in Washington, D....ange of safety and,efficacy data on its TAXUS(R) E...
(Date:10/9/2008)...s for Increased Sales and Marketing Efforts to Acc...ip(R) System, MENLO PARK, Calif., Oct. 9 /PRNewsw...t of devices for the percutaneous repair of cardia...cutive team with the appointment of,Sean Cleary as...eting and,Chris Richardson, as vice president of s...
(Date:10/8/2008)...a., Oct. 8 /PRNewswire-USNewswire/ -- The facts ar... from HIV/AIDS in,sub-Saharan Africa. More than 35...frica have already died of AIDS. The Foundation fo...ure the dying and their families,find compassion a...,s,innovative partnering initiative links African ...
(Date:10/8/2008)...ab Program to be Discontinued and Headcount to be ...its Portfolio Review; Zanolimumab Program to be D... of Employees, COPE... A/S (OMX: GEN),announced today that it is discont...In addition, as a result of a portfolio review and...
Breaking Medicine Technology:Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 1The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 2The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 3The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 4The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 5The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 6New knock out gene model provides molecular clues to breast cancer 615 1New knock out gene model provides molecular clues to breast cancer 615 2New knock out gene model provides molecular clues to breast cancer 615 3Martek Announces Third Quarter 2007 Financial Results 613 1Martek Announces Third Quarter 2007 Financial Results 613 2Martek Announces Third Quarter 2007 Financial Results 613 3Martek Announces Third Quarter 2007 Financial Results 613 4Martek Announces Third Quarter 2007 Financial Results 613 5Martek Announces Third Quarter 2007 Financial Results 613 6Martek Announces Third Quarter 2007 Financial Results 613 7Martek Announces Third Quarter 2007 Financial Results 613 8Martek Announces Third Quarter 2007 Financial Results 613 9Martek Announces Third Quarter 2007 Financial Results 613 10Martek Announces Third Quarter 2007 Financial Results 613 11Martek Announces Third Quarter 2007 Financial Results 613 12IRIDEX Announces Closing of 245 0 Million Private Placement 608 1IRIDEX Announces Closing of 245 0 Million Private Placement 608 2IRIDEX Announces Closing of 245 0 Million Private Placement 608 3IRIDEX Announces Closing of 245 0 Million Private Placement 608 4
...akthrough Will Aid in Developing Therapies to Prev...RYVILLE, Calif., May 10, 2007 /PRNewswire/ -- Kine...lopment company, announced,today the first method ...es in animals through the pathway known as reverse...n mechanism by which excess,cholesterol can be rem...
...POLIS, France, May 11, 2007 /PRNewswire-FirstCall/...pdate on the phase 2a,study for NCX 1000, which is... Pharma Inc. A preliminary analysis of 11 patient...tension confirmed,the safety profile of NCX 1000 b...pport the continuation of this clinical trial. As ...
Other Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
... the womb! Mothers can prevent the occurrence of c...e course of life //just by having a nutritious die...vegetables like cabbage and broccoli. A new study ...titute at Oregon State University, done with labor...
...nics were developed by scientists with a vision to... all defective genes from the gene pool. // But no...ade to order. Though it sounds absurd, ‘why should...To some parents with disabilities like deafness an...
...indicated that blood tests which were designed to ... good //as cholesterol tests , or blood pressure t... veritable risk indicator. Doctors have been mak...d which they interpreted as indicators of a heart ...
..., effectiveness and reliability of LASIK and LASEK...etween the two types of laser eye// surgery. The ...researcher, is published in the December 2006 issu...f Ophthalmology. "Although there have been many s...
Other Medicine News:Health News:Cancer Prevention Begins During Pregnancy 2Health News:Cancer Prevention Begins During Pregnancy 3Health News:Can Defective Babies Be Made To Order? 2Health News:Study Compares LASIK and LASEK Eye Surgery 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: